Prime Nordic has invested in Cereno Scientific, a company that is developing a new preventive drug that normalises the body’s own defense system against blood clots – to be used on the global market for the treatment of complications resulting from thrombosis-related cardiovascular diseases.
Based on years of research, preclinical studies and preliminary human studies, Cereno Scientific is now developing a new drug with the aim to solve one of the greatest needs in the prevention of cardiovascular diseases.
Cereno Scientificʼs concept is unique because there are currently no clinical therapies that optimise the bodyʼs clot-dissolving system (fibrinolytic system) that is triggered when the blood clotting (coagulation) and wound healing starts after a vascular injury occurs. Cereno Scientificʼs concept is based on a unique new formulation of valproic acid: CS1. CS1 restores the balance between the systems and the risk of thrombosis in myocardial infarction and/or stroke decreases.
Prime Nordic believes that Cereno Scientific has a very competent and solid management team with a product portfolio that has a huge potential.
The share is listed on the Spotlight Stock Market and is trading under the ticker CRNO B (ISIN: SE0008241558)
For more information, press only:
Kevin Shinduke Kevin.Shinduke@primenordic.com